Bacteriochlorin a, a new photosensitizer in photodynamic therapy. In vivo results.
The photosensitizing properties of bacteriochlorin a (BCA), a nontoxic derivative of bacteriochlorophyll a, were investigated in vivo. BCA has an absorption band at a wavelength at which tissue penetration is optimal (760 nm), and it shows preferential tumor retention in Greene melanoma implanted in the anterior chamber of rabbit eyes. A dose of 20 mg/kg BCA was administered IV at 4-7 mm tumor diameter; 24 hr later the tumor was irradiated with near-infrared light (30 min, 760 nm, 150-280 J/cm2). On the day after the irradiation it appeared that tumor growth had stopped: fluorescein angiography showed nonperfusion of the tumor. Histopathology after enucleation showed subtotal tumor necrosis with occasionally small clusters of viable cells around a blood vessel and at the tumor periphery. Neither BCA nor light alone had any effect on the eye or melanoma.
Schuitmaker
J J
JJ
Department of Ophthalmology, State University of Leiden, The Netherlands.
van Best
J A
JA
van Delft
J L
JL
Dubbelman
T M
TM
Oosterhuis
J A
JA
de Wolff-Rouendaal
D
D
D000818:Animals; D000867:Anterior Chamber / Q000473:pathology / Q000528:radiation effects; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005451:Fluorescein Angiography; D007275:Injections, Intravenous; D008027:Light; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009368:Neoplasm Transplantation; D010778:Photochemotherapy; D011166:Porphyrins / Q000627:therapeutic use*; D011817:Rabbits
D011166:Porphyrins; C065423:bacteriochlorin a